HOUSTON, Sept. 7, 2021 /PRNewswire/ -- Marker
Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage
immuno-oncology company specializing in the development of
next-generation T cell-based immunotherapies for the treatment of
hematological malignancies and solid tumor indications, today
announced that the Company will present at three upcoming virtual
investor conferences in September.
Conference Details
H.C. Wainwright Annual Global Investment
Conference
Company Presenter: Anthony H. Kim, Chief Financial Officer
Date: Monday, September 13, 2021
Time: On-demand beginning at 7:00 a.m.
ET
Oppenheimer Fall Healthcare Life Sciences & MedTech
Summit
Company Presenter: Mythili
Koneru, M.D., Ph.D., Chief Medical Officer
Date: Wednesday, September 22,
2021
Time: 9:05 a.m. ET
Cantor Fitzgerald Global Healthcare
Conference
Fireside Chat
Date: Monday, September 27, 2021
Time: 10:40 a.m. ET
Live webcasts of the presentations will be accessible from the
Investors section of the company's website at
markertherapeutics.com and will be available for replay
following the event.
About Marker Therapeutics, Inc.
Marker Therapeutics,
Inc. is a clinical-stage immuno-oncology company specializing in
the development of next-generation T cell-based immunotherapies for
the treatment of hematological malignancies and solid tumor
indications. Marker's cell therapy technology is based on the
selective expansion of non-engineered, tumor-specific T cells that
recognize tumor associated antigens (i.e. tumor targets) and kill
tumor cells expressing those targets. This population of T cells is
designed to attack multiple tumor targets following infusion into
patients and to activate the patient's immune system to produce
broad spectrum anti-tumor activity. Because Marker does not
genetically engineer its T cell therapies, we believe that our
product candidates will be easier and less expensive to
manufacture, with reduced toxicities, compared to current
engineered CAR-T and TCR-based approaches, and may provide patients
with meaningful clinical benefit. As a result, Marker believes its
portfolio of T cell therapies has a compelling product profile, as
compared to current gene-modified CAR-T and TCR-based
therapies.
To receive future press releases via email, please visit:
https://www.markertherapeutics.com/email-alerts.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/marker-therapeutics-to-present-at-three-upcoming-september-investor-conferences-301370677.html
SOURCE Marker Therapeutics, Inc.